Objective: To assess the value of dynamic monitoring of soluble human lymphocytic antigen-I (sHLA-I) in the prediction of graft-versus-host disease (GVHD) after allogeneic peripheral blood stem cell transplantation (PBSCT).
Method: Sandwich enzyme-linked immunosorbent assay (ELISA) was used to quantitatively detect serum sHLA-I. The serum samples for testing were added into W6 32 monoclonal antibody-coated microtiter plate and incubated with anti-beta2m HRP followed by color development with the addition of the substrate. Serum sHLA-I level was measured in 63 healthy blood donors of Shanghai and in 24 PBSCT recipients before and and at different time points after the operation.
Result: No changes in sHLA-I levels occurred in allogeneic PBSCT recipients without GVHD or with only grade I GVHD, but sHLA-I reached high levels in patients suffering GVHD II-IV(P<0.05), which was effectively lowered by the application of immunosuppressants.
Conclusion: Measurements of sHLA-I levels can be valuable for monitoring GVHD after PBSCT.